Literature DB >> 33846873

Use of population PK/PD approach to model the thrombin generation assay: assessment in haemophilia A plasma samples spiked by a TFPI antibody.

Raphaël Crépin1, Claire Morin2, Aurélie Montmartin3, Brigitte Tardy-Poncet3, Pierre Chelle4.   

Abstract

The thrombin generation (TG) assay is a well-established tool to capture the clotting potential of any healthy or haemophiliac subject. It measures ex vivo the kinetics of thrombin activation throughout the coagulation. Clinical studies allowed to create two databases gathering the coagulation factor levels and the thrombin generation profile of 40 healthy and 40 haemophiliac A (HA) subjects. Besides, portions of all HA samples were spiked with increasing levels of a TFPI antibody (considered as a possible therapeutic target) and corresponding TG profiles were determined. The non-linear mixed-effect (NLME) modelling aims at describing and explaining the experimentally observed important variability of the TG curves between subjects and the individual effects of spiking with a TFPI antibody. The models consist of an empirical description of the TG kinetics, accounting for an additive residual error and between-subject variability on its parameters. Factor VIII and TFPI were found to significantly explain and reduce the variability of the TG of haemophilia A samples. Besides, the model is shown to correctly reproduce the variability in the response to the ex vivo spiking with the TFPI antibody, by combining the empirical description of TG to a simple Hill equation that accounts for the binding between TFPI and different doses of its antibody. Such models can be useful for clinical practice, with the analysis and comparison of the distributions of TG profiles in healthy and haemophilia populations; and also for research, with the analysis of the effect of TFPI and its neutralization on individual TG profiles.

Entities:  

Keywords:  Coagulation; Empirical model; Non-linear mixed-effects modelling; PK/PD model; Thrombin generation assay

Mesh:

Substances:

Year:  2021        PMID: 33846873     DOI: 10.1007/s10928-021-09752-1

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  23 in total

Review 1.  Phenotyping the clotting system.

Authors:  H C Hemker; S Béguin
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

2.  Measurement of global haemostasis in severe haemophilia A following factor VIII infusion.

Authors:  S J Lewis; E Stephens; G Florou; N J Macartney; L S Hathaway; J Knipping; P W Collins
Journal:  Br J Haematol       Date:  2007-08-02       Impact factor: 6.998

3.  Prediction of individual factor VIII or IX level for the correction of thrombin generation in haemophilic patients.

Authors:  P Chelle; A Montmartin; M Piot; L Ardillon; B Wibaut; B Frotscher; M Cournil; C Morin; B Tardy-Poncet
Journal:  Haemophilia       Date:  2018-06-29       Impact factor: 4.287

4.  Thrombin generation and bleeding in haemophilia A.

Authors:  K E Brummel-Ziedins; M F Whelihan; M Gissel; K G Mann; G E Rivard
Journal:  Haemophilia       Date:  2009-06-26       Impact factor: 4.287

5.  Thrombin generation and phenotypic correlation in haemophilia A.

Authors:  C P Beltrán-Miranda; A Khan; A R Jaloma-Cruz; M A Laffan
Journal:  Haemophilia       Date:  2005-07       Impact factor: 4.287

6.  Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.

Authors:  Yesim Dargaud; Suzette Béguin; Anne Lienhart; Raed Al Dieri; Christine Trzeciak; Jean Claude Bordet; H Coenraad Hemker; Claude Negrier
Journal:  Thromb Haemost       Date:  2005-03       Impact factor: 5.249

7.  Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.

Authors:  A W J H Dielis; E Castoldi; H M H Spronk; R van Oerle; K Hamulyák; H Ten Cate; J Rosing
Journal:  J Thromb Haemost       Date:  2007-11-06       Impact factor: 5.824

8.  Is thrombin generation the new rapid, reliable and relevant pharmacological tool for the development of anticoagulant drugs?

Authors:  Séverine Robert; Jérémie Ghiotto; Bernard Pirotte; Jean-Louis David; Bernard Masereel; Lionel Pochet; Jean-Michel Dogné
Journal:  Pharmacol Res       Date:  2008-12-24       Impact factor: 7.658

9.  Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile.

Authors:  E Santagostino; M E Mancuso; A Tripodi; V Chantarangkul; M Clerici; I Garagiola; P M Mannucci
Journal:  J Thromb Haemost       Date:  2009-01-21       Impact factor: 5.824

10.  A new paradigm for personalized prophylaxis for patients with severe haemophilia A.

Authors:  Xavier Delavenne; Edouard Ollier; Anne Lienhart; Yesim Dargaud
Journal:  Haemophilia       Date:  2020-02-26       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.